According to media reports, if enough women agree to the settlement, it will effectively end as many as 3,800 cases in federal and state courts in New Jersey and Missouri. According to the terms of the preliminary settlement granted by Judge Brian Martinotti 95 percent of the plaintiffs must participate in the agreement. If more than 5 percent of plaintiffs refuse the offer, Merck can walk away from the deal, Martinotti said.
“The settlement is a fair resolution of this litigation,” the judge said. “This is a lump-sum settlement of $100 million that covers the entire litigation nationwide.”
READ MORE NuvaRing LEGAL NEWS
New Jersey-based Merck is not admitting any wrongdoing under the settlement and continues to believe NuvaRing is a safe contraceptive. A spokesperson for Merck said the company continues to “monitor the safety of the medicine.”
The settlement compensates women for three classes of injuries arising from blood clots, specifically, deep-vein thrombosis, pulmonary embolisms and death. The settlement structured so that women with more severe injuries will qualify for larger payments.
The consolidated cases are In Re NuvaRing Products Litigation, 08-md-01964, U.S. District Court, Eastern District of Missouri (St. Louis). The consolidated New Jersey cases are In RE: NuvaRing Litigation, BER-L-3081-09, Superior Court of New Jersey (Bergen County).